DIACC-3010 is under clinical development by Evexta Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DIACC-3010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DIACC-3010 overview

DIACC-3010 is under development for the treatment of triple negative breast cancer and gastric cancer and aggressive lymphomas. The drug candidate is administered through the oral route. It is a dual inhibitor of p70S6K/Akt1/3. It is a new chemical entity. It was under development for the treatment of gastric cancer, HER2 positive and negative metastatic breast cancer, colon cancer, adenocystic carcinoma of the salivary gland (third line), recurrent small-cell lung cancer (third line), ovarian cancer (second line), pancreatic cancer (second line), glioblastoma multiforme (GBM), pancreatic cancer and small-cell lung cancer.

Evexta Bio overview

Evexta Bio, formerly Diaccurate, is a biopharmaceutical company, which focuses on the exploration and development of innovative oncology treatments. The company’s pipeline products include Rupitasertib and EVX020, which have novel mechanisms of action across several indications. Rupitasertib is an optimized S6K inhibitor with efficient AKT1/AKT3 control of the feedback loop, and EVX020 is an sole-in-class KIF20A kinesin inhibitor. These products are primarily uses for the treatment of various types of cancer, including refractory ER+ HER2- metastatic breast cancer, and hematological and solid tumors. The company has partnerships with various institutes such as CNRS, Paoli-Calmettes Institute and Merck KGaA among others. Evexta Bio is headquartered in Paris, France.

For a complete picture of DIACC-3010’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.